CO4820439A1 - Compuestos y metodos para la deteccion y la prevencion de la infeccion por el t. cruzi - Google Patents

Compuestos y metodos para la deteccion y la prevencion de la infeccion por el t. cruzi

Info

Publication number
CO4820439A1
CO4820439A1 CO98075441A CO98075441A CO4820439A1 CO 4820439 A1 CO4820439 A1 CO 4820439A1 CO 98075441 A CO98075441 A CO 98075441A CO 98075441 A CO98075441 A CO 98075441A CO 4820439 A1 CO4820439 A1 CO 4820439A1
Authority
CO
Colombia
Prior art keywords
compounds
detection
methods
cruzi
cruzi infection
Prior art date
Application number
CO98075441A
Other languages
English (en)
Inventor
Steven G Reed
A W Skeiky Yasir
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of CO4820439A1 publication Critical patent/CO4820439A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proveen compuestos y métodos para el diagnóstico de lainfección por el Trypanosoma cruzi. Los compuestos presentados son polipéptidos o anticuerpos de los mismos, que contienen uno o más epitopos de los antígenos del T. Cruzi. Los compuestos resultan de utilidad en una variedad de inmunoensayos para la detección de la infección por T. Cruzi. Los compuestos de polipéptidos también resultan útiles en las vacunas y en las composiciones farmacéuticas para inducir una inmunidad protectora contra el mal de Chagas en individuos expuestos al T. Cruzi.
CO98075441A 1997-12-18 1998-12-18 Compuestos y metodos para la deteccion y la prevencion de la infeccion por el t. cruzi CO4820439A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/993,674 US6228372B1 (en) 1997-04-15 1997-12-18 Compounds and methods for the detection and prevention of T. cruzi infection

Publications (1)

Publication Number Publication Date
CO4820439A1 true CO4820439A1 (es) 1999-07-28

Family

ID=25539818

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98075441A CO4820439A1 (es) 1997-12-18 1998-12-18 Compuestos y metodos para la deteccion y la prevencion de la infeccion por el t. cruzi

Country Status (8)

Country Link
US (1) US6228372B1 (es)
EP (1) EP1038000A1 (es)
JP (1) JP2002508506A (es)
AR (1) AR014132A1 (es)
AU (1) AU1805799A (es)
BR (1) BR9813637A (es)
CO (1) CO4820439A1 (es)
WO (1) WO1999031246A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6419933B1 (en) * 1995-11-14 2002-07-16 Corixa Corporation Compounds and methods for the detection and prevention of T.cruzi infection
US6228372B1 (en) 1997-04-15 2001-05-08 Corixa Corporation Compounds and methods for the detection and prevention of T. cruzi infection
EP1945248A4 (en) * 2005-11-03 2008-12-31 Inbios Internat Inc COMPOSITIONS AND METHODS FOR DETECTING A TRYPANOSOMA CRUZI INFECTION
US7749717B2 (en) * 2006-10-19 2010-07-06 Abbott Laboratories Methods for the detection and diagnosis of Trypanosoma cruzi infection
CA2710761C (en) * 2007-12-27 2019-01-08 Abbott Laboratories Anti-t. cruzi antibodies and methods of use
BRPI0913972B1 (pt) 2008-07-03 2018-06-26 Infectious Disease Research Institute Polipeptídeo de fusão compreendendo antígenos de leishmania, polinucleotídeo, composição farmacêutica, bem como métodos para detecção de infecção e para identificação de leishmaniose e kit diagnóstico para detecção e identificação de leishmaniose
MX2017005644A (es) * 2014-11-06 2017-06-29 Hoffmann La Roche Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870006A (en) 1986-07-24 1989-09-26 Codon Antigenic material for a chagas' disease detection system
WO1990002564A1 (en) 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
BR9006039A (pt) 1990-11-28 1992-07-14 Fundacao Oswaldo Cruz Processo para preparacao de antigeno conjugado a atividade enzimatica,composicao a base de conjugado enzima-antigeno para utilizacao em diagnostico imunologico e kits de diagnostico imunologico da doenca de chagas a base da dita composicao,para aplicacao individual e/ou em inqueritos epidemiologicos
US5304371A (en) 1992-02-14 1994-04-19 Lasys Corporation Peptide for diagnosing and immunizing against T. cruzi infection
TW246717B (es) 1992-07-10 1995-05-01 Abbott Lab
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
US6228372B1 (en) 1997-04-15 2001-05-08 Corixa Corporation Compounds and methods for the detection and prevention of T. cruzi infection
US5916572A (en) 1995-11-14 1999-06-29 Corixa Corporation Compounds and methods for the detection and prevention of T. cruzi infection

Also Published As

Publication number Publication date
WO1999031246A1 (en) 1999-06-24
AU1805799A (en) 1999-07-05
JP2002508506A (ja) 2002-03-19
BR9813637A (pt) 2001-12-04
AR014132A1 (es) 2001-02-07
EP1038000A1 (en) 2000-09-27
US6228372B1 (en) 2001-05-08

Similar Documents

Publication Publication Date Title
ES2180754T3 (es) Compuestos y metodos para la deteccion de infeccion por t. cruzi.
DK0528859T3 (da) Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
Mitsuyasu et al. Heterogeneity of epidemic Kaposi's sarcoma. Implications for therapy
BG95337A (bg) Ваксиниране и методи срещу заболявания,резултат от патогенни отговори на т-клетъчно специфични популации
SE8604007D0 (sv) Vaccin och immunoanalyser for forvervat immunbristsyndrom (aids)
PT714444E (pt) Atenuacao de um epitopo imunodominante de um antigenio para utilizacao em vacinas e imunoterapias para plantas, animais e homens
AR020102A1 (es) Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
NO991524L (no) Vaksiner
AR073452A1 (es) Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis
CO4820439A1 (es) Compuestos y metodos para la deteccion y la prevencion de la infeccion por el t. cruzi
ATE375514T1 (de) Zusammensetzungen und methoden zur detektion einer trypanosoma cruzi infektion
ES2168520T3 (es) Compuestos y metodo para la deteccion y prevencion de infeccion por t. cruzi.
NO923778D0 (no) Multippel sklerose t-celle-reseptor
ES2061705T3 (es) Procedimiento de obtencion de un preparado antigenico de toxoplasma gondii y sus aplicaciones diagnosticas y profilacticas.
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
ES2118720T3 (es) Produccion y utilizacion de agentes antihelminticos e inmunogenos protectores.
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos
DE69525058D1 (de) Präsentation von aus lipoarabinomannan bestehenden antigenen an t-zellen durch cd1 moleküle
ES2057579T3 (es) Peptidos e1 y c de rubeola.
Sanchez et al. Immunological response to Vibrio cholerae O1 infection and an oral cholera vaccine among Peruvians
ES2090331T3 (es) Ctaa 28a32, antigeno reconocido por mca 28a32.
AR020852A1 (es) Antigenos de vacuna de leptospira para la prevencion de leptospirosis
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas